{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'Pregnancy tests for females of childbearing potential (FCBP)', 'Vital signs', 'Body weight and waist circumference', 'Clinical laboratory tests', 'Statistical Methods', 'This study will randomize approximately 255 subjects to either apremilast 30 mg BID or placebo', 'in a 2:1 ratio, respectively.', 'Assuming a placebo DLQI Responder proportion of 0.50 at Week 16, a minimum total sample', 'size of 210 subjects (140 allocated to apremilast 30 mg and 70 allocated to placebo) is needed to', 'detect a 0.20 difference in the DLQI Responder proportions between apremilast and placebo with', 'at least 0.807 power using a two-sided test at the 0.05 level of significance. This sample size', 'calculation was determined using the commercial software EaST, Version 6.3. Allowing for an', '18% discontinuation rate prior to Week 16, the sample size was revised from a total of 210', 'subjects to a final sample size of 255.', 'The primary analysis for the primary endpoint at Week 16 will be the Cochran-Mantel-Haensze -', '(CMH) test adjusted for the stratification factor at randomization (ie, the 5 manifestation types).', 'This form of the CMH test will use the sample sizes in each of the strata as weights when', 'estimating the adjusted difference in the treatment proportions, constructing 95% Wald', 'confidence intervals for the difference, and conducting a statistical test of no difference between', 'the treatment proportions (ie, H0: TAPR - TPBO = 0 as the null hypothesis).', 'All reasonable attempts will be made to prevent missing data from occurring in this study,', 'especially at Week 16. However, in the case of missing data at Week 16 a multiple imputation', '(MI) method will be incorporated into the primary analysis. The aim of the multiple imputation', 'approach is to incorporate a representative random sample in place of the missing data such that', 'unbiased estimation and valid statistical inferences (ie, confidence intervals and hypothesis', 'testing) can be made.', 'Confidential and Proprietary', '9', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen, Inc.', 'TABLE OF CONTENTS', 'TITLE PAGE', '1', 'PROTOCOL SUMMARY', '6', '1.', 'INTRODUCTION', '17', '1.1.', 'Disease Background', '17', '1.2.', 'Compound Background', '17', '1.3.', 'Rationale', '18', '1.3.1.', 'Study Rationale and Purpose', '18', '1.3.2.', 'Rationale for the Study Design', '18', '2.', 'STUDY OBJECTIVES AND ENDPOINTS', '20', '3.', 'OVERALL STUDY DESIGN', '23', '3.1.', 'Study Design', '23', '3.2.', 'Study Duration for Subjects', '24', '3.3.', 'End of Trial', '25', '4.', 'STUDY POPULATION', '26', '4.1.', 'Number of Subjects', '26', '4.2.', 'Inclusion Criteria', '26', '4.3.', 'Exclusion Criteria', '27', '5.', 'TABLE OF EVENTS', '29', '6.', 'PROCEDURES', '32', '6.1.', 'Screening Period', '32', '6.2.', 'Treatment Period', '33', '6.2.1.', 'End of Treatment', '34', '6.3.', 'Follow-up Period', '34', '6.3.1.', 'Post-Treatment Observational Follow-up', '34', '6.4.', 'Efficacy Assessments', '34', '6.4.1.', 'The Dermatology Life Quality Index (DLQI)', '34', '6.4.2.', 'Static Physicians Global Assessment (sPGA) of Visible Locations', '35', '6.4.3.', 'Scalp Physician Global Assessment (ScPGA)', '35', '6.4.4.', 'Nail Assessments/Nail Psoriasis Severity Index (NAPSI)', '35', '6.4.5.', 'Modified static Physicians Global Assessment of Genitalia (Modified', 'sPGA-G)', '35', '6.4.6.', 'Palmoplantar Psoriasis Physicians Global Assessment (PPPGA)', '36', 'Confidential and Proprietary', '10', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}